Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...

Supplementary insurance coverage for complementary health services (Yes) 202 55.0 Has a family physician (Yes) 308 83.5 Comorbid anxiety disorder ... professional of GAD in the past 12 months ...

Mind Medicine Inc., a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health ...

About Generalized Anxiety Disorder (GAD) GAD is a common condition associated with significant impairment that adversely affects millions of people. GAD results in fear, continuing anxiety ...

Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...

Building on our scientifically rigorous Phase 2b study, which demonstrated efficacy that far exceeds today’s standard of care and a favorable tolerability profile, our Phase 3 studies are designed to ...

For the first time ever, researchers are administering LSD to patients in a Phase 3 clinical trial. The new study focuses on whether the psychedelic can be used to effectively treat generalized ...

Most people worry, but for those with generalized anxiety disorder, worries are chronic and lead to symptoms like exhaustion, nausea, and trouble sleeping. The first step toward treatment is ...

A generalized anxiety disorder or GAD is completely different from normal feelings of anxiousness. While most of us feel anxious about certain happenings and things in our lives, GAD happens when ...